Abstract
The trinem sanfetrinem (GV 104326) was administered as the oral hexetil prodrug GV 118819X in two dose levels to six healthy volunteers. A single dose equivalent to 125 mg of sanfetrinem was administered, followed 6 weeks later by a single dose equivalent to 500 mg of sanfetrinem. The concentrations of the drug in plasma, cantharidin-induced inflammatory fluid, and urine were measured with a microbiological assay. The stability of sanfetrinem was studied in serum and inflammatory fluid. The mean peak concentrations in plasma of 0.77 and 2.47 microg/ml were attained at 1.1 and 2.0 h after the 125- and 500-mg doses, respectively. Mean peak concentrations in inflammatory exudate of 0.26 and 0.86 microg/ml were attained at 2.80 and 2.67 h after the 125- and 500-mg doses, respectively. The mean terminal elimination half-lives in plasma were 1.33 and 1.97 h for the 125- and 500-mg doses, respectively. The half-lives in the inflammatory fluid were 1.66 and 1.74 h for the 125- and 500-mg doses, respectively. The overall penetration of the drug into the inflammatory fluid was 51.4 and 47.0% for the 125- and 500-mg doses, respectively. Mean urine recovery was greater following 500 mg (24.15%) than after 125 mg (18.4%) of sanfetrinem. Sanfetrinem was relatively unstable in the inflammatory exudate in vitro (half-life, 5.5 h), and this could explain the poor penetration of the drug in the inflammatory exudate observed in this study.
Full Text
The Full Text of this article is available as a PDF (189.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Di Modugno E., Erbetti I., Ferrari L., Galassi G., Hammond S. M., Xerri L. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria. Antimicrob Agents Chemother. 1994 Oct;38(10):2362–2368. doi: 10.1128/aac.38.10.2362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Drusano G. L. An overview of the pharmacology of imipenem/cilastatin. J Antimicrob Chemother. 1986 Dec;18 (Suppl E):79–92. doi: 10.1093/jac/18.supplement_e.79. [DOI] [PubMed] [Google Scholar]
- Wise R. Comparative microbiological activity and pharmacokinetics of cefprozil. Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):839–845. doi: 10.1007/BF02111350. [DOI] [PubMed] [Google Scholar]
- Wise R., Gillett A. P., Cadge B., Durham S. R., Baker S. The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis. 1980 Jul;142(1):77–82. doi: 10.1093/infdis/142.1.77. [DOI] [PubMed] [Google Scholar]
- Wise R., O'Sullivan N., Johnson J., Andrews J. M. Pharmacokinetics and tissue penetration of ampicillin and brobactam following oral administration of 2085P. Antimicrob Agents Chemother. 1992 May;36(5):1002–1004. doi: 10.1128/aac.36.5.1002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wise R. The pharmacokinetics of the oral cephalosporins--a review. J Antimicrob Chemother. 1990 Dec;26 (Suppl E):13–20. doi: 10.1093/jac/26.suppl_e.13. [DOI] [PubMed] [Google Scholar]